Sun Pharmaceutical’s consolidated revenues, however, are expected to rise 13.2 percent on a year-on-year basis aided by growth in US specialty products and domestic formulations portfolio
Sun Pharmaceutical’s consolidated revenues, however, are expected to rise 13.2 percent on a year-on-year basis aided by growth in US specialty products and domestic formulations portfolio
English 
हिन्दी